WFAG
ABBV icon

Wescott Financial Advisory Group’s AbbVie ABBV Stock Holding History

Wescott Financial Advisory Group’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$204K Buy
+811
New +$174K 0.02% 193

Other funds holding ABBV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Wescott Financial Advisory Group's ABBV Position: Q2 2026 in Review

Wescott Financial Advisory Group opened a new position in AbbVie (ABBV) in Q2 2026: 811 shares worth $204K. The stake represents 0.02% of the portfolio and ranks #193 among its holdings.

4,192 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Wescott Financial Advisory Group held 811 shares of AbbVie worth $204K as of Q2 2026.
  • AbbVie was a new Wescott Financial Advisory Group position in Q2 2026.
  • AbbVie made up 0.02% of Wescott Financial Advisory Group's portfolio in Q2 2026, its #193 holding.
  • 4,192 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Wescott Financial Advisory Group's 13F filing for Q2 2026, filed 4 Aug 2026.